Reply to Crane et al., 'Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir'.
Pedrol
Enric
E
Deig
Elisabet
E
D000225:Adenine / Q000009:adverse effects / Q000031:analogs & derivatives*; D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D007668:Kidney / Q000187:drug effects*; D008297:Male; D063065:Organophosphonates / Q000009:adverse effects*; D012189:Retrospective Studies; D000068698:Tenofovir
D019380:Anti-HIV Agents; D063065:Organophosphonates; D000068698:Tenofovir; D000225:Adenine